Biohaven’s Life Without CGRP Inhibitors Gets Off To A Rocky Start
Data Mixed In Spinocerebellar Ataxia Study, But Zavegepant PDUFA Date Set
Executive Summary
With the sale of its migraine portfolio to Pfizer pending, Biohaven said troriluzole – a lead asset in the pipeline soon to be spun out in a new company – failed in a Phase III trial.
You may also be interested in...
Pfizer To Put Big Marketing Muscle Behind Migraine With Biohaven Purchase
Pfizer’s $11.6bn acquisition of the company brings it full rights to the oral migraine drug Nurtec ODT and nasal spray zevegepant, with aims to build a $6bn migraine franchise.
Biohaven Returns To Well With Bristol License, Acquires Channel Biosciences
With Nurtec and zavegepant in hand from Bristol, Biohaven tries for another success with a spinal muscular atrophy asset. It will move into epilepsy indications with the buyout of Channel, a subsidiary of Knopp.
Biohaven’s Migraine Empire Expands As Zavegepant Conquers Phase III
The company will seek US FDA approval after intranasally administered zavegepant passes its second pivotal test in the treatment of migraine attacks, followed by ex-US approvals with partner Pfizer.